SynAct Pharma AB (STO:SYNACT)

Sweden flag Sweden · Delayed Price · Currency is SEK
18.98
-0.12 (-0.63%)
Aug 14, 2025, 1:56 PM CET
111.83%
Market Cap 999.43M
Revenue (ttm) n/a
Net Income (ttm) -82.18M
Shares Out 52.33M
EPS (ttm) -1.92
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 79,612
Average Volume 134,988
Open 19.00
Previous Close 19.10
Day's Range 18.80 - 19.22
52-Week Range 7.31 - 23.45
Beta 0.99
RSI 41.41
Earnings Date Aug 20, 2025

About SynAct Pharma AB

SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. It is also developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases.... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 6
Stock Exchange Nasdaq Stockholm
Ticker Symbol SYNACT
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.